Prosight Management, LP Immuneering Corp Transaction History
Prosight Management, LP
- $320 Million
- Q2 2024
A detailed history of Prosight Management, LP transactions in Immuneering Corp stock. As of the latest transaction made, Prosight Management, LP holds 550,000 shares of IMRX stock, worth $1.33 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
550,000Holding current value
$1.33 Million% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding IMRX
# of Institutions
60Shares Held
9.65MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$4.55 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.59 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$2.31 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD859KShares$2.08 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.79 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $63.9M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...